Fig. 1

Erbin improves survival rate and alleviates cognitive impairment in CLP-induced septic mice. A Experimental design. 6–8 week male C57BL/6 J mice were subjected to sham or CLP operation, then STF083010 (2.5 mg/kg) or DMSO was given at 1 h, 24 h, and 48 h after CLP. The hippocampus of different groups was collected for tests 24 h. The OFT, NORT, and MWM tests were carried out from the 7th to the 14th day. B Primary microglia and BV2 cells were incubated with STF083010 (30 µΜ) or DMSO, then were added LPS (500 ng/ml) 2 h later, and finally were administrated with nigericin (10 µΜ) 4 h after adding LPS. The cells and culture medium supernatants were collected for testing 45 min after incubation. C Primary microglia were plated onto 6-well plates and then treated with DMSO, STF083010, or LPS/nigericin at the appointed times. 45 min after nigericin was added, new media were adopted to replace the old medium, and the microglia were continued to culture for 24 h. Then the supernatant was collected and added into the HT22 cells’ medium and cultured for 12 h. D 7-Day survival rate of mice after CLP. E Traveled distance of the four groups of mice treated in the OFT. F Preference index of the four groups of mice in the NORT. G Escape latency, H time spent in the target quadrant, and I numbers of crossings through the platform were recorded in each group (n = 10 per group). J, K Erbin expressions in the hippocampus after CLP were analyzed by western blot (n = 3 per group). *p < 0.05, **p < 0.01 vs. Sham group; ^#p < 0.05, ^##p < 0.01 vs. CLP group